# Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes

Article · Stephen James Nicholls, Imre J. Pavo, Deepak L. Bhatt, John B. Buse, Stefano Del Prato, Steven E. Kahn, Abraham Michael Lincoff, Darren K. McGuire, Debra Lee Miller, Michael Albrecht Nauck, Hiroshi Nishiyama, Steven E. Nissen, Naveed A. Sattar, Govinda J. Weerakkody, Russell J. Wiese, Bernard Zinman, Sophia Zoungas, Jan Basile, Melanie J Davies, Francesco Giorgino, Monika Kellerer, Linong Ji, Tamás T. Várkonyi, Venu Menon, Jonathan C. Broder and 2 more

- Archive id: doi:10.1056/nejmoa2505928
- Published: 2025-12-17
- Venue: New England Journal of Medicine
- DOI: https://doi.org/10.1056/nejmoa2505928
- PMID: 41406444
- Citations: 220
- Source URL: https://doi.org/10.1056/nejmoa2505928
- PDF: http://publicatio.bibl.u-szeged.hu/38555/1/Varkonyi.pdf
- Provenance: openalex

_Abstract not reproduced: its license does not permit redistribution. See the source URL._

Topics: [GLP-1 & Incretin Therapies](https://space-kitty.com/topics/glp1-metabolic)

Cited in dossiers:
- [GLP-1 & Incretin Therapies: State of the Field (October 2026)](https://space-kitty.com/dossiers/glp1-metabolic)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.